Loading…
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Patent Eligibility Restoration Act of 2024
Client: CHIESI USA, INC. · Firm: CHIESI USA, INC.
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions; H.R. 9474 - Continuing Appropriations and Extension Act, 2025.
Patent Eligibility Restoration Act of 2024
Client: CHIESI USA, INC. · Firm: CHIESI USA, INC.
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions; H.R. 9474 - Continuing Appropriations and Extension Act, 2025. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
CHIESI USA, INC. via CHIESI USA, INC.
2026 · third_quarter · Q3
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation. Implementation of the Joe Fiandra Access to Home Infusion Act of 2025 (Public Law 119-21), including CMS rulemaking and home infusion therapy reimbursement issues.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2026 · second_quarter · Q2
Source: Senate LDA
H.R. 5376 - Build Back Better Act - Drug Pricing and Orphan Drug Tax Credit.
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2026 · first_quarter · Q1
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2025 · fourth_quarter · Q4
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2025 · third_quarter · Q3
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2025 · second_quarter · Q2
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2025 · first_quarter · Q1
Issues related to Therapies for Rare Diseases - no specific legislation. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2024 · fourth_quarter · Q4
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions; H.R. 9474 - Continuing Appropriations and Extension Act, 2025. General healthcare access and innovation matters, and regulatory pathway topics - no specific legislation.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2024 · third_quarter · Q3
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions; H.R. 9474 - Continuing Appropriations and Extension Act, 2025.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2024 · second_quarter · Q2
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2024 · first_quarter · Q1
Issues related to Therapies for Rare Diseases - Reauthorization of Pediatric Rare PRV, Modifications to IRA, and Access to Home Infusions.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2023 · fourth_quarter · Q4
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2023 · third_quarter · Q3
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2023 · second_quarter · Q2
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2023 · first_quarter · Q1
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2022 · fourth_quarter · Q4
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2022 · third_quarter · Q3
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2022 · second_quarter · Q2
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2022 · first_quarter · Q1
Issues related to Therapies for Rare Diseases - Orphan Drug Act, Accelerated Approval Pathway.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2021 · fourth_quarter · Q4
H.R. 5376 - Build Back Better Act - Drug Pricing and Orphan Drug Tax Credit.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2021 · third_quarter · Q3
Issues related to rare and ultra rare diseases, including monitoring regulatory and legislative policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2021 · second_quarter · Q2
Issues related to rare and ultra rare diseases, including monitoring regulatory and legislative policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2021 · first_quarter · Q1
Issues related to rare and ultra rare diseases, including monitoring regulatory and legislative policies.
CHIESI USA, INC. via CHIESI USA, INC.
2020 · fourth_quarter · Q4
Issues related to rare and ultra rare diseases, including monitoring regulatory and legislative policies.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
CHIESI USA, INC. via CHIESI USA, INC.
2020 · fourth_quarter · RR
Issues related to rare and ultra rare diseases, including monitoring regulatory and legislative policies.